ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements
Aayush Wellness Limited has submitted its Annual Report for the financial year 2025-26. The report includes financial statements, statutory reports, and corporate information.
Aayush Wellness Limited has issued the notice for its 42nd Annual General Meeting scheduled for September 29, 2026. The meeting will be held via video conferencing.
Aayush Wellness Limited announced the re-appointment of Gavadu Patil as Non-Executive Non-Independent Director and the appointment of A. Raghavendra Rao & Associates as Statutory Auditor.
Aayush Wellness approved the reappointment of a director and the appointment of new statutory auditors. The board also scheduled the 42nd Annual General Meeting.
Aayush Wellness confirmed to BSE that they have no undisclosed information that would impact the company's recent share price movement or performance.
Aayush Wellness Limited has launched its new Lung Care Tablets, expanding its preventive healthcare portfolio. This product targets consumers concerned about respiratory health.
Aayush Wellness Limited announced postal ballot results with shareholders approving the appointment of statutory auditors and two non-executive directors. All three ordinary resolutions passed with significant majority.
Aayush Wellness reported Q1 FY27 consolidated revenue of ₹33.11 Crore, reflecting 46% YoY growth. Consolidated PAT stood at ₹1.42 Crore for the quarter.
Aayush Wellness Ltd reported revenue from operations of ₹33.1 Cr (+46.5% YoY) and net profit of ₹1.4 Cr (+16.7% YoY) for Q1 FY27.
Aayush Wellness Ltd has scheduled a Board Meeting for August 13, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.
Aayush Wellness Ltd has filed its shareholding pattern for the quarter ended June 30, 2026. This is a standard regulatory filing under Regulation 31.
Aayush Wellness Limited issued a Postal Ballot Notice for shareholder approval. Agenda includes appointing new Statutory Auditors and regularising two Non-Executive Directors' appointments.
Aayush Wellness approved the appointment of new statutory auditors and the regularisation of two non-executive directors. A postal ballot process for member approval was also initiated.
Aayush Wellness reported ₹155.48 Crore revenue for FY26, a 112% year-on-year increase. Net profit grew 18.26% to ₹3.98 Crore, driven by expansion in preventive healthcare segments.
Aayush Wellness Ltd reported revenue from operations of ₹48.4 Cr (+116.1% YoY) and net profit of ₹0.6 Cr (-45.5% YoY) for Q4 FY26.
Aayush Wellness reported a 115% increase in consolidated total income to ₹158.09 Crore for FY26. Net profit grew 18.26% YoY to ₹3.98 Crore.
Aayush Wellness Limited scheduled its board meeting for May 29, 2026. The board will consider audited standalone and consolidated financial results for fiscal 2026.
Aayush Wellness Limited appointed M/s. A. Raghavendra Rao & Associates as Statutory Auditors to fill a casual vacancy. The firm brings extensive expertise across various industrial sectors.
Aayush Wellness launched Aayush Dia Shield Tablets, entering India's ₹36,656 Crore metabolic health market. The herbal supplement targets 230 million Indians currently affected by diabetes.
Aayush Wellness Limited confirmed it does not qualify as a Large Corporate under SEBI's debt securities framework for FY 2026. The company reported outstanding borrowings of ₹4.00 Crore as of March 31, 2026, which is below the ₹1,000 Crore threshold. Consequently, specialized debt-raising requirements for large entities are not applicable.
Aayush Wellness Limited has launched 'Liver Detox Tablets' to address the growing demand for preventive liver health solutions in India. The herbal formulation targets lifestyle-related liver disorders and is available on the company's official website. This launch aligns with the company's strategy to expand its condition-led preventive healthcare portfolio in the $18 billion nutraceutical market.